What are the main drivers of type 2 diabetes (T2D) and why does the diabetes epidemic continue to grow despite a wealth of information? Join series host Dr. John Anderson, past president of ADA, who practices internal medicine at the Frist Clinic, as he interviews fellow experts on the main drivers of T2D and how clinicians can optimize patient outcomes in this changing disease area. Bonus episode with a focus on the indispensable role of pharmacists in T2D care hosted by Todd Eury, founder and CEO of the Pharmacy Podcast Network. This podcast is sponsored by Novo Nordisk and is intended for clinicians.
The Indispensable Role of Pharmacists in T2D Care
16:31Join episode host, Todd Eury, founder and CEO of the Pharmacy Podcast Network, as he discusses the indispensable role of pharmacists in T2D care with Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP and Rohit Moghe, PharmD, MSPH, CDCES. These pharmacist experts will share insights on why the role of pharmacists is so important in T2D care, including reviewing data on how pharmacist involvement improves measurable outcomes for patients with T2D. To raise awareness, they will also review T2D treatment recommendations from major medical societies.This program is intended for clinicians. The information presented is aligned with the views and opinions of the speakers and is sponsored by Novo Nordisk. This podcast is not to be used as medical advice and is intended for educational purposes only.Faculty Presenters:Todd Eury, BSCEOPharmacy Podcast Network Brownsville, PennsylvaniaDiana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCPEndocrine Clinical Pharmacist and Director of Education and Training in Diabetes TechnologyThe Cleveland Clinic Cleveland, OhioRohit Moghe, PharmD, MSPH, CDCESAmbulatory Care & Population Health Clinical PharmacistTrinity Health Mid-Atlantic Langhorne, Pennsylvania
Should We Be Thinking Differently About Type 2 Diabetes?
23:14Should we be thinking differently about type 2 diabetes (T2D)? Join experts in T2D: Dr John Anderson (primary care provider), Ms Lucia Novak (Nurse Practitioner), and Dr Joshua Stolker (cardiologist) as they talk about ways to think differently about type 2 diabetes and consider factors in addition to A1C such as comorbidities, recommendations on managing patients with T2D from national endocrinology and cardiology societies, and how the cardiology community can work with the diabetology community to provide the best care for patients with T2D. This podcast is sponsored by Novo Nordisk and is intended for clinicians.Faculty Presenters:John E. Anderson, MDInternal Medicine and DiabetesThe Frist ClinicNashville, TennesseeLucia M. Novak, MSN, ANP-BC, BC-ADMPresident and OwnerDiabetes Consulting ServicesNorth Bethesda, MarylandCo-Executive DirectorCapital Health & Metabolic Center of Capital Diabetes & Endocrine AssociatesCamp Springs and Silver Spring, MarylandJoshua M. Stolker, MDSTEMI DirectorMercy Heart and VascularWashington, MissouriAdjunct Associate ProfessorSaint Louis UniversitySt. Louis, Missouri
The Increased Risk of Cardiovascular Disease in Patients With T2D
15:53What are the prevalence, increased risk, and impact of cardiovascular disease (CVD) among patients with type 2 diabetes (T2D)? Join experts: Dr John Anderson (primary care physician), Dr Pam Taub (cardiologist), and Dr Mark Greathouse (cardiologist) as they review the relationship between T2D and CVD, including how T2D exacerbates CVD and the risk from CVD, and what the national medical associations recommend for patients with T2D and CVD.This podcast is sponsored by Novo Nordisk and is intended for clinicians.Faculty Presenters:John E. Anderson, MDInternal Medicine and DiabetesThe Frist ClinicNashville, TennesseePam Taub, MD, FACCCardiologist and Professor of MedicineDirector, Cardiac Rehabilitation and Wellness CenterUC San Diego HealthSan Diego, CaliforniaMark Greathouse, MDSenior Clinical CardiologistSt. Clair HealthPittsburg, Pennsylvania
Understanding Insufficient GLP-1 Activity in T2D
9:16What is the impact of insufficient GLP-1 activity in type 2 diabetes (T2D)? Join experts in T2D: Dr John Anderson, Dr Javier Morales, and Dr Richard Pratley as they review the role of GLP-1 in glucose regulation, consider the impact of insufficient GLP-1 activity on pancreatic beta cells in patients with T2D, and discuss possibilities to overcome insufficient GLP-1 activity in patients with T2D.This podcast is sponsored by Novo Nordisk and is intended for clinicians.Faculty Presenters:John E. Anderson, MDInternal Medicine and DiabetesThe Frist ClinicNashville, TennesseeJavier Morales, MD, FACP, FACEInternal Medicine, Diabetes, and Primary CareAssociate Clinical ProfessorHofstra/Northwell School of Medicine at the Donald and Barbara Zucker School of MedicineLong Island, New YorkRichard E. Pratley, MDInternal Medicine and DiabetesAdventHealth Diabetes InstituteOrlando, Florida
The Role of Endogenous GLP-1
15:30What is the role of endogenous GLP-1 in the pathophysiology of T2D? Join multidisciplinary experts in T2D: Dr John Anderson, Dr Vivian Fonseca, and Dr Jim Gavin as they discuss the fascinating history of GLP-1 discovery and the role of endogenous GLP-1 in the pathophysiology of T2D.This podcast is sponsored by Novo Nordisk and is intended for Healthcare Practitioners.Faculty Presenters:John E. Anderson, MDInternal Medicine and DiabetesThe Frist ClinicNashville, TennesseeJames R. Gavin III, MD, PhDClinical Professor of Medicine, Emory UniversityChief Medical Officer, Healing Our Village, Inc.Atlanta, GeorgiaVivian A. Fonseca, MD, FRCPProfessor of Medicine, Assistant Dean for ResearchTulane UniversityNew Orleans, Louisiana
Beta-Cell Dysfunction: A Driver of T2D?
11:27What do you know about the role of beta-cell dysfunction in the pathophysiology of type 2 diabetes (T2D)? Join primary care experts in T2D: Dr. John Anderson, Dr. Stephen Brunton and Dr. James LaSalle as we discuss the beta-cell function and its critical role in T2D pathogenesis, what clinicians know or should know about it and how it is measured in the clinic, and how our current knowledge of beta-cell function in T2D may affect future research on T2D treatment.This podcast is sponsored by Novo Nordisk and is intended for clinicians. The opinions expressed are those of the speakers and not Novo Nordisk.Faculty Presenters:John E. Anderson, MDInternal Medicine and DiabetesThe Frist ClinicNashville, TennesseeStephen Brunton, MD, FAAFPExecutive DirectorPrimary Care Metabolic GroupWinnsboro, South CarolinaJames LaSalle, DO, FAAFPMedical Arts of Excelsior Springs, Inc.Excelsior Springs, Missouri
Act Early to Lighten the Heavy Burden of T2D
18:44What is the burden of the type 2 diabetes (T2D) epidemic? Join experts in T2D: Dr. John Anderson (primary care provider), Dr. Susan Cornell (clinical pharmacist and certified diabetes care and education specialist) and Dr. Doron Schneider (primary care provider) as they discuss the enormous physical, emotional, psychological and economic burden of T2D and its comorbidities on the US healthcare system and on their patients and what they, as clinicians need to do to ease this burden.This podcast is sponsored by Novo Nordisk and is intended for clinicians.Faculty Presenters:John E. Anderson, MDInternal Medicine and DiabetesThe Frist ClinicNashville, TennesseeSusan Cornell, BS, PharmD, CDCES, FAPhA, FADCESAssociate Director of Experiential EducationProfessor of Pharmacy PracticeMidwestern University Chicago College of PharmacyDowners Grove, IllinoisDoron Schneider, MD, MBA, FACPVice President, Population Health ServicesTandigm HealthWest Conshohocken, Pennsylvania